医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Jabil Receives Prestigious 2023 Shingo Prize in Shanghai

2024年03月07日 AM10:00
このエントリーをはてなブックマークに追加


 

SHANGHAI

Today, Jabil Inc. (NYSE: JBL) announced that its site in Shanghai has received the Shingo Prize, the world’s highest standard for organizational and operational excellence. The award from the Shingo Institute — a program of the Jon M. Huntsman School of Business at Utah State University — recognizes organizations that achieve operational excellence by applying the principles of the Shingo Model.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240306460676/en/

The Shingo Institute sent a group of eight examiners to assess Jabil’s site in Shanghai in December 2023. (Photo: Business Wire)

The Shingo Institute sent a group of eight examiners to assess Jabil’s site in Shanghai in December 2023. (Photo: Business Wire)

Jabil’s site in Shanghai is the largest medical device manufacturer recognized with the Shingo Prize since 2008, according to the Shingo Institute.

“Shanghai’s commitment to operational excellence goes to the very heart of what the company stands for,” said Gerald “JJ” Creadon, Executive Vice President of Global Operations. “It starts with employees doing the right thing the first time, following standardized processes and procedures while being supported by a lean culture that is embedded in everything we do. This award represents the work of thousands of our people who demonstrate this exceptional culture every day.”

Jabil established its site in Shanghai in 2002 and now employs over 3,000 people. It offers electronics manufacturing services to clients in various sectors such as automotive, 5G, networking and storage, industrial, and healthcare. The Shanghai site is certified by the FDA and NMPA. It has a wide range of capabilities such as new product introduction (NPI), kitting, Build-to-Order (BTO), Configure-to-Order (CTO), and high-level, complex assembly and integration. The site also boasts an ISO Class 7 microbiological and chemical lab.

“This is an incredible recognition. A key component of achieving this prestigious award is being able to demonstrate throughout the organization that the key tenets of our culture are understood and are part of the team’s DNA,” said Mike Mahaz, Senior Vice President of Global Business Units.

With more than 100 sites across the globe, Jabil’s commitment to operational excellence is a driving force towards the company’s ability to navigate and implement practical solutions and options that best serve the needs of its customers given the commonality of systems embedded throughout the company’s seamless network of factories around the globe.

In Jabil’s journey for the award, eight examiners from the Shingo Institute evaluated the site based on the institute’s rigorous principles, such as Cultural Enablers, Continuous Improvement, and Enterprise Alignment. The team will receive the award at the 36th Annual Shingo Conference held from May 9-10 in Orlando, Florida.

This is Jabil’s second Shingo Prize recognition. The company’s site in Bray, Ireland, was awarded the Shingo Prize in 2021.

About Jabil:

At Jabil (NYSE: JBL), we are proud to be a trusted partner for the world’s top brands, offering comprehensive engineering, manufacturing, and supply chain solutions. With over 50 years of experience across industries and a vast network of over 100 sites worldwide, Jabil combines global reach with local expertise to deliver both scalable and customized solutions. Our commitment extends beyond business success as we strive to build sustainable processes that minimize environmental impact and foster vibrant and diverse communities around the globe. Discover more at www.jabil.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240306460676/en/

CONTACT

Aileen Han

Director, Enterprise Marketing and Communications

Aileen_Han@jabil.com

同じカテゴリーの記事 

  • Ifinatamab Deruxtecan Continues to Demonstrate Promising Objective Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial
  • Huonslab Announces Positive Results from In Vivo comparative PK study of Trastuzumab/HyDIFFUZETM compared with marketed rHuPH20 co-formulation with Trastuzumab
  • Rapid Medical™、TIGERTRIEVER™13を用いたDISTALS臨床試験の中間安全性解析で、中血管閉塞の安全性の懸念がないことを報告
  • Amneal and Shilpa Announce U.S. FDA Approval of BORUZU™, the First Ready-to-Use Version of Bortezomib for subcutaneous administration
  • JCR Pharmaceuticals’ Data Presentations at SSIEM Annual Symposium 2024 Highlight Investigational Treatments for Lysosomal Storage Disorders